Porza, Switzerland

Claudia Cappellini

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2006-2009.


% Patents Active = 100.0


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2006-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Claudia Cappellini: Innovator in Chewable Tablet Technology

Introduction

Claudia Cappellini is a notable inventor based in Porza, Switzerland. She has made significant contributions to the field of pharmaceutical innovations, particularly in the development of chewable tablets. With a total of 2 patents to her name, Claudia is recognized for her dedication to enhancing medication compliance among children and juveniles.

Latest Patents

One of Claudia's latest patents is a chewable tablet containing lysine. This innovative tablet is designed to improve compliance among users, especially children and juveniles. The formulation aims to make medication more palatable and easier to consume, thereby addressing a common challenge in pediatric healthcare.

Career Highlights

Claudia Cappellini is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. Her work focuses on developing innovative solutions that cater to the needs of young patients. Claudia's expertise in pharmaceutical sciences has positioned her as a key player in her field.

Collaborations

Throughout her career, Claudia has collaborated with esteemed colleagues such as Valter Gianesello and Michael David Marocchi. These partnerships have fostered a creative environment that encourages the exchange of ideas and the development of groundbreaking products.

Conclusion

Claudia Cappellini's contributions to the field of chewable tablet technology highlight her commitment to improving healthcare for children. Her innovative approach and collaborative spirit continue to inspire advancements in pharmaceutical formulations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…